]>
IRCT20201212049690N1 IRCT 2020-12-28 Islamic Azad University Evaluation of Hydroxy Choloroquine on Generalized Vitiligo Vulgaris Evaluation of oral Hydroxy Choloroquine on treatment of Generalized Vitiligo Vulgaris 2019-05-22 anticipated 15 Complete https://irct.ir/trial/53083 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2-3 Generalized Vitiligo vulgaris. Intervention group: HCQ was orally administered 400 mg daily (∼6.5 mg/Kg of body weight) by 15 patients with generalized vitiligo for three months. Patients were evaluated monthly and skin re-pigmentation was assessed using the VASI SCORE.. Yes - There is a plan to make this available What will be shared: All data can be shared after patients are made unidentifiable When: Data can be accessible 6 months after results are published To whom: Data will be available for researchers in universities and other scientific institutes Conditions: Carrying out analysis on data is permitted Where to obtain: Data can be accessible through sending an email to the corresponding author How to obtain: After sending a request email to the corresponding author, data will be sent in 1 month Comments:
public Soudabeh Sazgarnia
2nd Floor, No. 152, Nastaran 18 St, Malek Abad Blvd
Mashhad Iran (Islamic Republic of) 9185735386 +98 21 3761 5556 soodabe.sn@gmail.com Islamic Azad University scientific Pouran Layegh
No 52, B Bldg, Kouhsangi Residental complex, Kouhsangi 15 Alley, Kouhsangi Ave
Mashhad Iran (Islamic Republic of) 9176774448 +98 21 3849 4724 layeghpo@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Iran (Islamic Republic of) Involvement of at least 10% of body surface At least one month has passed since the last treatment for the patient Not receiving any other treatment Not taking other drugs at the same time with immunomodulatory and immunosuppressive effects Over 7 years old Weight over 35 kg Do not take drugs that interfere with hydroxychloroquine, such as Image result for artemether and Dapsone and Lumfanterin 7 years no limit Both Glucose-6-phosphate dehydrogenase deficiency Retinopathy Acute gastrointestinal disorders Myasthenia gravis Psoriasis Renal failure Sensitivity to antimalarial compounds Hepatic failure L80 Vitiligo Treatment - Drugs Intervention group: HCQ was orally administered 400 mg daily (∼6.5 mg/Kg of body weight) by 15 patients with generalized vitiligo for three months. Patients were evaluated monthly and skin re-pigmentation was assessed using the VASI SCORE. Score in Vasi Score. Timepoint: Before starting treatment, one-two-three month after start using drug. Method of measurement: Vasi Score. Islamic Azad University Approved 2019-04-17 Ethics committee of Islamic Azad University of Mashhad 2nd Floor, No. 152, Nastaran 18 St, Malek Abad Blvd Mashhad Razavi Khorasan Iran (Islamic Republic of)